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Objective: The serum adiponectin level decreases in patients with metabolic syndrome (MetS) and is an
inverse predictor of cardiovascular outcomes in hemodialysis (HD) patients. The aim of this study was to
investigate the relationship of adiponectin and MetS among HD patients.
Materials and Methods: Fasting blood samples were obtained from 101 HD patients. MetS and its
components were deﬁned using diagnostic criteria from the International Diabetes Federation.
Results: Forty-eight of the 101 HD patients (47.5%) had MetS. Adiponectin levels negatively correlated
with MetS among HD patients (p¼ 0.001). Univariate linear regression analysis showed that the pre-HD
body weight (p< 0.001); waist circumference (p¼ 0.001); body mass index (BMI; p< 0.001); hemo-
globin (p¼ 0.038); triglyceride level (p< 0.001); insulin level (p¼ 0.005); and homeostasis model
assessment of insulin resistance (p¼ 0.001) correlated negatively with the fasting serum adiponectin
levels, whereas the high-density-lipoprotein cholesterol (HDL-C; p< 0.001) level correlated positively
with the fasting serum adiponectin levels in the HD patients. Multivariate forward stepwise linear
regression analysis of the signiﬁcant variables showed that the HDL-C level (R2 change¼ 0.142, p¼ 0.001)
and BMI (R2 change¼ 0.078, p¼ 0.002) were independent predictors of fasting serum adiponectin levels
in HD patients.
Conclusion: The serum adiponectin concentration correlates inversely with MetS in HD patients. For
these patients, the HDL-C level and BMI are independent predictors of the serum adiponectin value.
Copyright  2011, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC.
All rights reserved.1. Introduction
Metabolic syndrome (MetS), a constellation of physical and
laboratory abnormalities, including hypertension, hyperglycemia,
dyslipidemia, and central obesity, affects about 47 million people in
the United States and places them at about a threefold increase in
risk for coronary artery disease and stroke [1e5]. MetS is associated
with chronic kidney disease (CKD) and increases cardiovascular
mortality [1,5].Buddhist Tzu Chi General
alien, Taiwan. Tel.: þ886 3
).
ddhist Compassion Relief Tzu ChiAdiponectin is a 247-amino acid protein that is produced largely
by white adipose tissue and has a wide range of effects in the
immune and inﬂammatory components of pathogenesis, such as
those in cardiovascular disease (CVD), Type 2 diabetes mellitus
(DM), and MetS [6,7]. Although the adiponectin level is generally
elevated in dialysis patients, it has been observed that dialysis
patients with relatively lower adiponectin levels have an increased
mortality rate [8e10].
Although hypoadiponectinemia has been found to be an inde-
pendent risk marker for MetS in Type 2 DM, in obese children and
adolescents and in middle and elderly populations, few studies
have examined the characteristics of adiponectin in maintenance
hemodialysis (HD) patients [11e13]. This study is intended to
investigate the adiponectin distribution and relationships with
MetS and the components of MetS in HD patients.Foundation. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Clinical and analytical characteristics of 101 hemodialysis patients
Parameter
Anthropometric
data
Height (cm) 154.43 8.16
Pre-HD body weight (kg) 60.88 13.39
Body mass index (kg/m2) 25.73 6.25
Systolic pressure (mmHg) 145.37 22.36
Waist circumference (cm) 88.02 10.75
Age (y) 62.00 13.62
HD duration (mo) 71.51 45.47
Diastolic pressure (mmHg) 78.00 14.26
Biochemical data White blood count (1000/uL) 6.58 3.09
Albumin (g/dL) 3.97 0.41
Triglyceride (mg/dL) 136.99 92.00
Fasting glucose (mg/dL) 143.83 65.57
Blood urea nitrogen (mg/dL) 60.95 15.47
C-reactive protein (mg/dL) 0.85 1.97
Kt/V (Gotch) 1.46 0.20
Adiponectin (mg/mL) 23.55 16.62
Hemoglobin (g/dL) 10.56 1.38
Total cholesterol (mg/dL) 160.05 39.56
High-density-lipoprotein cholesterol
(mg/dL)
43.54 16.81
Creatinine (mg/dL) 9.11 2.09
Intact parathyroid hormone (pg/mL) 239.23 226.01
Urea reduction ratio 0.76 0.05
Insulin (mU/dL) 23.54 33.60
Homeostasis model assessment of insulin
resistance
7.92 10.24
Causes of uremia Diabetes 28 (27.7)
Glomerulonephritis 19 (18.8)
Hypertension 37 (36.6)
others 17 (16.9)
Data are expressed as means standard deviations or n (%).
HD¼ hemodialysis.
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2.1. Patients
One hundred one HD patients, including 55 men and 46 women
with the same high-ﬂux polysulfone disposable artiﬁcial kidney (FX
class dialyzer; Fresenius Medical Care, Bad Homburg, Germany),
were enrolled in June 2009 at Dalin Tzu Chi General Hospital,
Chiayi, Taiwan. Patients from our HD program were invited to
participate in the study if they were older than 20 years, were
receiving standard 4-hour three-time weekly dialysis using stan-
dard bicarbonate dialysate, and had been on dialysis for at least 12
months. Patients were excluded if they had any acute infection,
a life expectancy of less than 3 months, malignancy, or refusal or
inability to provide informed consent for the study. The Protection
of Human Subjects Institutional Review Board at Tzu Chi Hospital
approved the study. The Kt/V and urea reduction ratio (URR) were
measured before dialysis and immediately after dialysis using
a formal, single-compartment dialysis urea kinetic model.
2.2. Anthropometric analysis
Body weight (BW) was measured to the nearest half kilogram
with the patient in light clothing without shoes. Height was
measured to the nearest half centimeter. Waist circumference was
measured in a horizontal plane, midway between the inferior
margin of the ribs and the superior border of the iliac crest. Body
mass index (BMI) was calculated as weight (kilograms) divided by
height squared (meters) [14].
2.3. Biochemical investigations
Fasting blood samples of approximately 0.5 mL were drawn to
measure the complete blood count (Sysmex K-1000; Sysmex,
Bohemia, NY, USA) and other factors, and were immediately
centrifuged at 3000 g for 10minutes. Serum samples were stored at
4C and used for biochemical analyses within 1 hour of collection.
Serum levels of BUN, creatinine, fasting glucose, total cholesterol,
triglycerides (TGs), high-density-lipoprotein cholesterol (HDL-C),
albumin, and C-reactive protein (CRP) were measured using
a commercial kit (COBAS Integra 800; Roche Diagnostics, Basel,
Switzerland). The serum intact parathyroid hormone levels were
measured using a commercially available enzyme-linked immu-
nosorbent assay (Diagnostic Systems Laboratories, Webster, TX,
USA) [14]. Patients were classiﬁed as having secondary hyper-
parathyroidism if the intact parathyroid hormone level was greater
than 300 pg/mL. Serum adiponectin (SPI- BIO, Montigny le Bre-
tonneux, France) concentrations were determined using
a commercially available enzyme immunoassay [14]. The limit of
detection, calculated as the concentration of human adiponectin
corresponding to the blank average minus 3 standard deviations,
was 0.7 mg/mL. The inter- and intra-assay coefﬁcients of variation
for adiponectin were 7.3% and 6.4%, respectively. The serum insulin
levels were measured using the microparticle enzyme immuno-
sorbent assay method by an autoanalyzer (Abbott Laboratories,
Abbott Park, IL, USA). Insulin resistance was evaluated using
a homeostasis model assessment of insulin resistance (HOMA-IR)
as follows: HOMA-IR¼ glucose (mg/dL) insulin (mU/mL)/405 [15].
2.4. MetS and its components
The presence of MetS was established using the International
Diabetes Federation deﬁnition [3]. Patients were diagnosed as
having MetS if they had central (abdominal) obesity with a waist
circumference greater than or equal to 90 cm (Chinese males) orgreater than or equal to 80 cm (Chinese females), plus two or more
of the following: (1) fasting serum glucose values of 110 mg/dL or
greater; (2) TG values of 150 mg/dL or greater; (3) HDL-C concen-
trations less than 40 mg/dL for males or less than 50 mg/dL for
females; or (4) blood pressure measurements of 130/85 mmHg or
higher or use of antihypertensive agents. The presence of Type 2
DM was established according to World Health Organization
criteria [4]. An individual was considered diabetic if the fasting
plasma glucose was 126 mg/dL or greater, 2-hour glucose during an
oral glucose tolerance test was 200 mg/dL or greater, or if antidia-
betic therapy (oral agent or insulin) was required.
2.5. Statistical analysis
Data were expressed as mean standard deviation. Categorical
variables were analyzed by the Chi-square test. Comparisons
between patients were performed using Student independent t test
(two-tailed) for parametric data or the Mann-Whitney U test for
parameters presenting with nonparametric distributions (TG,
fasting glucose, CRP, insulin, and HOMA-IR). Correlations of clinical
variables with serum adiponectin concentrations were evaluated
by univariate linear regression analysis. Variables signiﬁcantly
associated with adiponectin in HD patients were tested for inde-
pendence by multivariate stepwise linear regression analysis. Data
were analyzed using SPSS for Windows (version 13.0; SPSS Inc.,
Chicago, IL, USA). A p value less than 0.05 was considered statisti-
cally signiﬁcant.
3. Results
Biochemical and clinical characteristics of the 101 HD patients
are presented in Table 1. The causes of uremia included DM (n¼ 28;
27.7%); hypertensive nephrosclerosis (n¼ 37; 36.6%); glomerulo-
nephritis (n¼ 19; 18.8%); and others (n¼ 17; 16.9%).
Table 3
Clinical characteristics and fasting serum adiponectin levels of the 101 hemodialysis
patients
Characteristic n (%) Adiponectin
level (mg/mL)
p
Gender
Male 55 (54.5) 23.09 16.11 0.765
Female 46 (45.5) 24.09 17.34
Diabetes
No 71 (70.3) 25.63 17.44 0.052
Yes 30 (29.7) 18.62 13.49
Hypertension
No 44 (43.6) 24.52 20.00 0.607
Yes 57 (56.4) 22.80 13.59
Hyperparathyroidism
No 78 (77.2) 22.67 16.68 0.328
Yes 23 (22.8) 26.54 16.41
Metabolic syndrome
No 53 (52.5) 28.81 18.65 0.001*
Yes 48 (47.5) 17.75 11.71
Angiotensin-converting enzyme inhibitor
No 88 (87.1) 23.73 17.15 0.774
Yes 13 (12.9) 22.31 12.96
Angiotensin receptor blocker
No 68 (67.3) 21.59 15.42 0.088
Yes 33 (32.7) 27.60 18.44
b-Blocker
No 71 (70.3) 23.56 17.56 0.992
Yes 30 (29.7) 23.52 14.41
Calcium channel blocker
No 56 (55.4) 23.13 14.37 0.779
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sented in Table 2. Forty-eight patients (47.5%) were diagnosed as
having MetS. HD patients with MetS had a signiﬁcantly higher pre-
HD BW (p< 0.001), waist circumference (p< 0.001), BMI
(p< 0.001), TG level (p¼ 0.001), insulin level (p< 0.001), and
HOMA-IR (p< 0.001), but a signiﬁcantly lower HDL-C level
(p¼ 0.002), URR (p¼ 0.004), and Kt/V (p¼ 0.047) than those
without MetS. No statistically signiﬁcant differences were found
between HD patients with and without MetS in terms of gender,
age, HD duration, DM, hypertension, hyperparathyroidism, systolic
blood pressure, or diastolic blood pressure.
Clinical characteristics and fasting serum adiponectin values for
the 101 HD patients are presented in Table 3. The fasting serum
adiponectin level negatively correlated with MetS among HD
patients (p¼ 0.001). No statistically signiﬁcant differences in adi-
ponectin values were found as a function of gender; presence of
DM, hypertension, or hyperparathyroidism; or use of angiotensin-
converting enzyme inhibitors, angiotensin receptor blockers, b-
blockers, calcium channel blockers, or statins.
Univariate linear analysis of fasting serum adiponectin concen-
trations with clinical variables in HD patients is presented in
Table 4. The pre-HD BW (r¼0.374, p< 0.001); waist circumfer-
ence (r¼0.328, p¼ 0.001); BMI (r¼0.363, p< 0.001); hemo-
globin (r¼0.207, p¼ 0.038); TG level (r¼0.353, p< 0.001);
insulin level (r¼0.273, p¼ 0.005); and HOMA-IR (r¼0.317,
p¼ 0.001) correlated negatively with fasting serum adiponectin
values, whereas the HDL-C level (r¼ 0.377, p< 0.001) correlated
positively with the fasting serum adiponectin level in HD patients.
Analysis using multivariate stepwise linear regression of the
variables (pre-HD BW, BMI, hemoglobin, TG, insulin, HOMA-IR, andTable 2
Comparison of individuals with and without metabolic syndrome
Items No metabolic
syndrome (n¼ 53)
Metabolic
syndrome
(n¼ 48)
p
Gender (male) 31 (58.5) 24 (50.0) 0.392
Diabetes mellitus 13 (24.5) 17 (35.4) 0.232
Hypertension 27 (50.9) 30 (62.5) 0.242
Hyperparathyroidism 14 (26.4) 9 (18.8) 0.359
Age (y) 61.45 13.51 62.60 13.84 0.673
Hemodialysis duration (mo) 78.51 50.72 63.77 37.90 0.104
Height (cm) 154.85 9.54 153.96 6.39 0.587
Pre-hemodialysis body weight
(kg)
55.20 11.25 67.15 12.84 <0.001*
Waist circumference (cm) 81.01 7.53 95.76 8.15 <0.001*
Body mass index (kg/m2) 22.56 5.21 27.49 5.78 <0.001*
White blood count (1000/uL) 6.51 3.74 6.65 2.18 0.829
Hemoglobin (g/dL) 10.40 1.48 10.74 1.25 0.214
Albumin (g/dL) 3.98 0.36 3.97 0.47 0.899
Total cholesterol (mg/dL) 161.17 37.87 158.81 41.70 0.767
Triglyceride (mg/dL) 115.58 84.86 160.63 94.61 0.001*
High-density-lipoprotein
cholesterol (mg/dL)
48.36 15.82 38.23 16.41 0.002*
Fasting glucose (mg/dL) 154.36 79.50 142.15 46.35 0.324
Blood urea nitrogen (mg/dL) 59.32 15.86 62.75 14.99 0.268
Creatinine (mg/dL) 8.89 1.99 9.36 2.19 0.264
C-reactive protein (mg/dL) 0.95 2.32 0.72 1.51 0.747
Systolic blood pressure
(mmHg)
145.87 22.37 144.81 22.57 0.814
Diastolic blood pressure
(mmHg)
76.42 13.30 79.75 15.20 0.243
Intact parathyroid hormone
(pg/mL)
259.03 244.81 217.36 203.57 0.403
Insulin (mU/dL) 16.10 32.49 31.75 33.21 <0.001*
Homeostasis model assessment
of insulin resistance
5.29 8.86 10.82 10.96 <0.001*
Urea reduction ratio 0.78 0.05 0.75 0.004 0.004*
Kt/V (Gotch) 1.50 0.22 1.42 0.16 0.047*
Data are expressed as means standard deviations or n (%).
*p< 0.05 versus other group.
Yes 45 (44.6) 24.07 19.21
Statin
No 96 (95.0) 23.71 16.93 0.665
Yes 5 (5.0) 20.39 9.03
*p< 0.05 was considered statistically signiﬁcant after the Student t test.HDL-C) signiﬁcantly associated with fasting serum adiponectin in
HD patients revealed that the HDL-C level (R2¼ 0.142, p¼ 0.001)
and BMI (R2 ¼ 0.078, p¼ 0.002) were independent predictors
associated with serum adiponectin in HD patients (Table 5).Table 4
Correlation of fasting serum adiponectin levels and clinical variables by univariate
linear regression analyses among the 101 hemodialysis patients
Items Beta p
Age (y) 0.084 0.402
Hemodialysis duration (mo) 0.182 0.068
Height (cm) 0.040 0.689
Pre-hemodialysis body weight (kg) 0.374 <0.001*
Waist circumference (cm) 0.328 0.001*
Body mass index (kg/m2) 0.363 <0.001*
White blood count (1000/uL) 0.179 0.073
Hemoglobin (g/dL) 0.207 0.038*
Albumin (g/dL) 0.066 0.515
Total cholesterol (mg/dL) 0.043 0.672
Triglyceride (mg/dL) 0.353 <0.001*
High-density-lipoprotein cholesterol (mg/dL) 0.377 <0.001*
Fasting glucose (mg/dL) 0.141 0.159
Blood urea nitrogen (mg/dL) 0.039 0.702
Creatinine (mg/dL) 0.096 0.340
C-reactive protein (mg/dL) 0.128 0.200
Systolic blood pressure (mmHg) 0.009 0.928
Diastolic blood pressure (mmHg) 0.094 0.348
Intact parathyroid hormone (pg/mL) 0.050 0.617
Insulin (mU/dL) 0.273 0.005*
Homeostasis model assessment of insulin resistance 0.317 0.001*
Urea reduction ratio 0.140 0.162
Kt/V (Gotch) 0.132 0.188
*p< 0.05 was considered statistically signiﬁcant after univariate linear analyses.
Table 5
Multivariate stepwise linear regression analysis of body weight, waist circumfer-
ence, body mass index, hemoglobin, triglyceride, insulin, homeostasis model
assessment of insulin resistance, and HDL-C: correlation with fasting serum adi-
ponectin level among 101 hemodialysis patients
Items Beta R2 R2 change p
HDL-C (mg/dL) 0.306 0.142 0.142 0.001*
Body mass index (kg/m2) 0.288 0.078 0.078 0.002*
*p< 0.05 is considered statistically signiﬁcant in the multivariate stepwise linear
regression analysis.
HDL-C¼ high-density-lipoprotein cholesterol.
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Results of this study showed that the fasting adiponectin level
was inversely associated with MetS in HD patients. HDL-C and BMI
were independent predictors associated with the serum adipo-
nectin in HD patients.
MetS has been postulated to be associated with insulin resis-
tance, hyperinsulinemia, and glucose intolerance, and has been
associated with potentially atherogenic lipoprotein proﬁles,
including hypertriglyceridemia, elevated apolipoprotein B, and
decreased HDL-C concentrations [2,3]. It causes major health
problems in Western populations and is estimated to affect at least
20% of the adult population and approximately 40% of adults older
than 60 years [2]. Previous studies revealed that MetS is associated
with reduced kidney function, is a signiﬁcant risk factor for CVD
andmortality in uremic patients, and predicts hospitalization in HD
patients [1,5,9,16,17]. According to International Diabetes Federa-
tion criteria, MetS occurs in about 62.4% of HD patients in the
United States, which is higher than that in the general population
[18]. The prevalence of MetS in our study was 47.5%, and patients
with MetS had a signiﬁcantly higher pre-HD BW; waist circum-
ference; BMI; and TG, insulin, and HOMA-IR levels, but a signiﬁ-
cantly lower HDL-C level, URR, and Kt/V than those without MetS.
Adiponectin, a unique insulin sensitizer adipocyte-derived
substance, plays an important role in regulating glucose and lipid
metabolism and in controlling energy homeostasis in insulin-
sensitive tissues [7]. A decrease in the circulating level of adi-
ponectin has been linked to insulin resistance, Type 2 DM,
atherosclerosis, and MetS [6,11e13]. Our previous study found that
the fasting adiponectin level was inversely associated with MetS in
peritoneal dialysis patients [19]. In this study, adiponectin was also
signiﬁcantly lower in HD patients with MetS.
Adiponectin levels correlate inversely with the HOMA-IR, TG
level, BMI, waist circumference, and insulin level, and correlate
positively with HDL-C levels in patients with CKD, DM, and HD
[11,16,20]. Serum adiponectin concentrations are increased in CKD,
HD, and peritoneal dialysis patients [8,9,19,21]. Adiponectin levels
were also found to be inversely correlated with BMI, HOMA-IR, and
TG level, but had no relationship with CRP in HD patients [8,21].
Our study found that the pre-HD BW; waist circumference;
hemoglobin; TG and insulin levels; and HOMA-IR correlated
negatively with the fasting serum adiponectin levels, whereas the
HDL-C level correlated positively with the fasting serum adipo-
nectin levels in HD patients.
Previous studies noted that b-blockers worsen insulin sensi-
tivity, and the use of angiotensin-converting enzyme inhibitors was
associated with an increase in plasma adiponectin in hypertensive
and DM patients [22e24]. There were no relationships between
therapeutic regimens and serum adiponectin in our HD patients.
Further studies are required to elucidate the relationship between
medication and adiponectin in HD patients.
There were some limitations of our study. First, this was a cross-
sectional study, which restricted the ability to compare causalrelationships between adiponectin levels and the variables inves-
tigated. Second, this study was performed in one hospital. The
number of patients was small, and more patients are needed for
further analysis. Third, the adiponectin levels were checked only
once, and we could not monitor intraindividual trends during long-
term HD. Another limitation was that the adiponectin enzyme
immunoassay kit used in the present study measures total serum
adiponectin but does not discriminate between low- and high-
molecular-weight (HMW) forms of the adipokine. Certain pharma-
cological interventions may inﬂuence serum adiponectin concen-
trations in humans. The HMW form of adiponectin possesses
bioactivity, whereas the low-molecular-weight form does not; the
function of the latter remains to be determined [25]. Plasma HMW
adiponectin levels have been negatively associated with visceral fat
area and positively associated with treatment with blockade of
the renin-angiotensin system and calcium channel blockers in
HD patients [26]. Additional studies will be required to ascertain
whether the concentration of HMWadiponectin in the serum of HD
patients is inversely associated with the presence of MetS and
whether drugs inﬂuence serum HMW adiponectin concentrations
in HD patients.
In conclusion, we found an inverse association between circu-
lating fasting adiponectin andMetS in HD patients. The HDL-C level
and BMI were independent predictors associated with the adipo-
nectin level in HD patients.Acknowledgment
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